Precipio achieves positive adjusted EBITDA, cash flow in Q4

Precipio (PRPO), has achieved two financial goals in the last quarter of 2024: Positive Adjusted EBITDA – Precipio reports Adjusted EBITDA of $0.4M for Q4-2024. Adjusted EBITDA is a non-GAAP metric that comprises EBITDA, less non-cash stock-based compensation expense and other significant or non-operating or expenses. Positive Cash flow. Precipio reports an increase of $0.3M in cash during Q4-2024. Of this improvement, $75,000 was due to directors’ fees paid in stock; the balance is cash flow from operations. The company said, “The combination of these two factors demonstrates the Company’s ability to achieve and sustain financial independence by generating enough positive cash flow from its pathology service division to fund ongoing R&D as well as continued, consistent investment in growing the high value product business. Management notes that the financial performance in future quarters may fluctuate from positive to negative due to various factors. One such occurrence may occur in Q1 when pathology business revenues and cash receipts are typically reduced by renewed insurance deductibles. Prior years’ experience indicates operating results will not be affected by these factors nearly as much in Q2. However, with the Company’s current cash reserves and growth pipeline, management believes it is on track to turn the corner and become a profitable company.”